Global Non-Invasive Cancer Diagnostics Market Size, Trends and Growth Opportunity, By Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other), By Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test (POCT), Hematology, Hemostasis), By Test Type (Urine Test, Imaging Test, Spectroscopy), By Application (Blood, Urine, Saliva), By End Users (Hospital and Clinics, Diagnostic Centers, Ambulatory Care, Others), By Region and forecast till 2030.
Global Non-Invasive Cancer Diagnostics Market
Global Non-Invasive Cancer Diagnostics Market was valued at USD 145 billion by 2022 and is slated to reach USD 245.19 billion by 2030 at a CAGR of 7.25% from 2023-2030.
Non-invasive cancer diagnostics is a process used to diagnose various cancer issues with the least amount of bodily incision possible, including cancer. Various approaches are typically used during the operation, including those for identifying genetic structure, biomarkers, molecular biology changes, and imaging technologies. Due to its non-invasive nature and lack of points or cuts, this procedure does not hurt the body.
Market Drivers
During the projection period, it is anticipated that technological developments in diagnostic testing will accelerate market expansion. For instance, Hologic, Inc. declared commercial access to the Genius Digital Diagnostics System in Europe in 2021. The next-generation cervical cancer screening system uses deep learning-based AI and cutting-edge volumetric imaging technology to help find precancerous lesions and cervical cancer cells in female patients. So, this is anticipated to promote market expansion. The two main drivers driving the growth of the cancer diagnostics market globally are the rise in cancer cases and the rise in the senior population. Globally, 19.3 million new cases of cancer were reported in 2020, according to GLOBOCAN, and 30.2 million new cases are anticipated in 2040. According to a data sheet from the World Health Organisation, cancer is responsible for about 1 in 6 deaths worldwide. In low- and middle-income nations, cancer deaths account for about 70% of all fatalities. This thereby accelerates market expansion.
Market Restraints
Numerous hospitals in undeveloped and developing countries are unable to purchase diagnostic imaging equipment because of high costs and financial restrictions. However, hospitals in these nations that cannot afford to buy brand-new, cutting-edge imaging systems choose rebuilt ones because to the rising need for diagnostic imaging in these countries. This constrains market expansion as a result of this factor.
Impact of COVID-19
Many people have postponed or cancelled cancer screenings due of the COVID-19 epidemic, including non-invasive diagnostic testing. This has resulted in a decrease in the demand for these tests as well as a reduction in revenue for the businesses that offer them. The COVID-19 pandemic has sped up the use of telemedicine, which enables patients to get treatment from a distance. This has made it possible for businesses who provide non-invasive cancer detection services to market their products through remote monitoring and virtual consultations. The necessity of early disease identification and cancer prevention has been made clear by the epidemic. This has raised funding for non-invasive cancer diagnostic research and development as well as awareness and education about cancer screening.
Market Segmentation
Global Non-Invasive Cancer Diagnostics Market is segmented into Type, Product Type, Test Type, Application and End User. By Type such as Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other. By Product Type such as Immunochemistry, Clinical Microbiology, Point of Care Test (POCT), Hematology, Hemostasis. By Test Type such as Urine Test, Imaging Test, Computerized Tomography, Magnetic Resonance Imaging, Nuclear Medicine Scans, X-ray/Mammography, Ultrasound, Spectroscopy. By Application such as Blood, Urine, Saliva. By End Users such as Hospital and Clinics, Diagnostic Centers, Ambulatory care, Others.
Regional Analysis
Global Non-Invasive Cancer Diagnostics Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market is dominated by North America due to the region's rising biotechnology and medical device industry presence and rising financing for R&D initiatives. Additionally, the market growth is boosted by this region's extensive use of cutting-edge technology. In light of the rising number of cancer patients and increased knowledge of minimally invasive diagnostic tools, Asia-Pacific is predicted to experience a large expansion in the market. Additionally, the market is developing due to expanding government initiatives for improved technology and more effective healthcare diagnosis.
Key Players
This report includes a list of numerous Key Players, namely Abbott (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (U.S.), Quest Diagnostics Incorporated. (U.S.), Merck KGaA, (Germany), Hologic, Inc. (U.S.), BD. (U.S.).
Market Taxonomy
By Type
• Lung Cancer
• Breast Cancer
• Solid Tumors
• Blood Cancer
• Ovarian Cancer
• Colorectal Cancer
• Other
By Product Type
• Immunochemistry
• Clinical Microbiology
• Point of Care Test (POCT)
• Hematology
• Hemostasis
By Test Type
• Urine Test
• Imaging Test
• Computerized Tomography
• Magnetic Resonance Imaging
• Nuclear Medicine Scans
• X-ray/Mammography
• Ultrasound
• Spectroscopy
By Application
• Blood
• Urine
• Saliva
By End Users
• Hospital and Clinics
• Diagnostic Centers
• Ambulatory care
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa
Global Non-Invasive Cancer Diagnostics Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Non-Invasive Cancer Diagnostics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Non-Invasive Cancer Diagnostics Market, By Type
5.1 Y-o-Y Growth Comparison, By Type
5.2 Global Non-Invasive Cancer Diagnostics Market Share Analysis, By Type
5.3 Global Non-Invasive Cancer Diagnostics Market Size and Forecast, By Type
5.3.1 Lung Cancer
5.3.2 Breast Cancer
5.3.3 Solid Tumors
5.3.4 Blood Cancer
5.3.5 Ovarian Cancer
5.3.6 Colorectal Cancer
5.3.7 Other
6 Global Non-Invasive Cancer Diagnostics Market, By Product Type
6.1 Y-o-Y Growth Comparison, By Product Type
6.2 Global Non-Invasive Cancer Diagnostics Market Share Analysis, By Product Type
6.3 Global Non-Invasive Cancer Diagnostics Market Size and Forecast, By Product Type
6.3.1 Immunochemistry
6.3.2 Clinical Microbiology
6.3.3 Point of Care Test (POCT)
6.3.4 Hematology
6.3.5 Hemostasis
7 Global Non-Invasive Cancer Diagnostics Market, By Test Type
7.1 Y-o-Y Growth Comparison, By Test Type
7.2 Global Non-Invasive Cancer Diagnostics Market Share Analysis, By Test Type
7.3 Global Non-Invasive Cancer Diagnostics Market Size and Forecast, By Test Type
7.3.1 Urine Test
7.3.2 Imaging Test
7.3.3 Computerized Tomography
7.3.4 Magnetic Resonance Imaging
7.3.5 Nuclear Medicine Scans
7.3.6 X-ray/Mammography
7.3.7 Ultrasound
7.3.8 Spectroscopy
8 Global Non-Invasive Cancer Diagnostics Market, By Application
8.1 Y-o-Y Growth Comparison, By Application
8.2 Global Non-Invasive Cancer Diagnostics Market Share Analysis, By Application
8.3 Global Non-Invasive Cancer Diagnostics Market Size and Forecast, By Application
8.3.1 Blood
8.3.2 Urine
8.3.3 Saliva
9 Global Non-Invasive Cancer Diagnostics Market, By End Users
9.1 Y-o-Y Growth Comparison, By End Users
9.2 Global Non-Invasive Cancer Diagnostics Market Share Analysis, By End Users
9.3 Global Non-Invasive Cancer Diagnostics Market Size and Forecast, By End Users
9.3.1 Hospital and Clinics
9.3.2 Diagnostic Centers
9.3.3 Ambulatory care
9.3.4 Others
10 Global Non-Invasive Cancer Diagnostics Market, By Region
10.1 Global Non-Invasive Cancer Diagnostics Market Share Analysis, By Region
10.2 Global Non-Invasive Cancer Diagnostics Market Share Analysis, By Region
10.3 Global Non-Invasive Cancer Diagnostics Market Size and Forecast, By Region
11 North America Non-Invasive Cancer Diagnostics Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Non-Invasive Cancer Diagnostics Market Share Analysis, By Type
11.3 North America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Product Type
11.4 North America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Test Type
11.5 North America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Application
11.6 North America Non-Invasive Cancer Diagnostics Market Size and Forecast, By End Users
11.7 North America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Country
11.7.1 U.S.
11.7.1.1 Market Size and Forecast, By Type
11.1.1.2 Market Size and Forecast, By Product Type
11.7.1.3 Market Size and Forecast, By Test Type
11.7.1.4 Market Size and Forecast, By Application
11.7.1.5 Market Size and Forecast, By End Users
11.7.2 Canada
11.7.2.1 Market Size and Forecast, By Type
11.1.2.2 Market Size and Forecast, By Product Type
11.7.2.3 Market Size and Forecast, By Test Type
11.7.2.4 Market Size and Forecast, By Application
11.7.2.5 Market Size and Forecast, By End Users
11.7.3 Mexico
11.7.3.1 Market Size and Forecast, By Type
11.1.3.2 Market Size and Forecast, By Product Type
11.7.3.3 Market Size and Forecast, By Test Type
11.7.3.4 Market Size and Forecast, By Application
11.7.3.5 Market Size and Forecast, By End Users
12 Europe Non-Invasive Cancer Diagnostics Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Non-Invasive Cancer Diagnostics Market Share Analysis, By Type
12.3 Europe Non-Invasive Cancer Diagnostics Market Size and Forecast, By Product Type
12.4 Europe Non-Invasive Cancer Diagnostics Market Size and Forecast, By Test Type
12.5 Europe Non-Invasive Cancer Diagnostics Market Size and Forecast, By Application
12.6 Europe Non-Invasive Cancer Diagnostics Market Size and Forecast, By End Users
12.7 Europe Non-Invasive Cancer Diagnostics Market Size and Forecast, By Country
12.7.1 Germany
12.7.1.1 Market Size and Forecast, By Type
12.1.1.2 Market Size and Forecast, By Product Type
12.7.1.3 Market Size and Forecast, By Test Type
12.7.1.4 Market Size and Forecast, By Application
12.7.1.5 Market Size and Forecast, By End Users
12.7.2 France
12.7.2.1 Market Size and Forecast, By Type
12.1.2.2 Market Size and Forecast, By Product Type
12.7.2.3 Market Size and Forecast, By Test Type
12.7.2.4 Market Size and Forecast, By Application
12.7.2.5 Market Size and Forecast, By End Users
12.7.3 UK
12.7.3.1 Market Size and Forecast, By Type
12.1.3.2 Market Size and Forecast, By Product Type
12.7.3.3 Market Size and Forecast, By Test Type
12.7.3.4 Market Size and Forecast, By Application
12.7.3.5 Market Size and Forecast, By End Users
12.7.4 Russia
12.7.4.1 Market Size and Forecast, By Type
12.1.4.2 Market Size and Forecast, By Product Type
12.7.4.3 Market Size and Forecast, By Test Type
12.7.4.4 Market Size and Forecast, By Application
12.7.4.5 Market Size and Forecast, By End Users
12.7.5 Italy
12.7.5.1 Market Size and Forecast, By Type
12.1.5.2 Market Size and Forecast, By Product Type
12.7.5.3 Market Size and Forecast, By Test Type
12.7.5.4 Market Size and Forecast, By Application
12.7.5.5 Market Size and Forecast, By End Users
12.7.6 Spain
12.7.6.1 Market Size and Forecast, By Type
12.1.6.2 Market Size and Forecast, By Product Type
12.7.6.3 Market Size and Forecast, By Test Type
12.7.6.4 Market Size and Forecast, By Application
12.7.6.5 Market Size and Forecast, By End Users
12.7.7 Rest of Europe
12.7.7.1 Market Size and Forecast, By Type
12.1.7.2 Market Size and Forecast, By Product Type
12.7.7.3 Market Size and Forecast, By Test Type
12.7.7.4 Market Size and Forecast, By Application
12.7.7.5 Market Size and Forecast, By End Users
13 Asia Pacific Non-Invasive Cancer Diagnostics Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Non-Invasive Cancer Diagnostics Market Share Analysis, By Type
13.3 Asia Pacific Non-Invasive Cancer Diagnostics Market Size and Forecast, By Product Type
13.4 Asia Pacific Non-Invasive Cancer Diagnostics Market Size and Forecast, By Test Type
13.5 Asia Pacific Non-Invasive Cancer Diagnostics Market Size and Forecast, By Application
13.6 Asia Pacific Non-Invasive Cancer Diagnostics Market Size and Forecast, By End Users
13.7 Asia Pacific Non-Invasive Cancer Diagnostics Market Size and Forecast, By Country
13.7.1 China
13.7.1.1 Market Size and Forecast, By Type
13.7.1.2 Market Size and Forecast, By Product Type
13.7.1.3 Market Size and Forecast, By Test Type
13.7.1.4 Market Size and Forecast, By Application
13.7.1.5 Market Size and Forecast, By End Users
13.7.2 Japan
13.7.2.1 Market Size and Forecast, By Type
13.7.2.2 Market Size and Forecast, By Product Type
13.7.2.3 Market Size and Forecast, By Test Type
13.7.2.4 Market Size and Forecast, By Application
13.7.2.5 Market Size and Forecast, By End Users
13.7.3 India
13.7.3.1 Market Size and Forecast, By Type
13.7.3.2 Market Size and Forecast, By Product Type
13.7.3.3 Market Size and Forecast, By Test Type
13.7.3.4 Market Size and Forecast, By Application
13.7.3.5 Market Size and Forecast, By End Users
13.7.4 South Korea
13.7.4.1 Market Size and Forecast, By Type
13.7.4.2 Market Size and Forecast, By Product Type
13.7.4.3 Market Size and Forecast, By Test Type
13.7.4.4 Market Size and Forecast, By Application
13.7.4.5 Market Size and Forecast, By End Users
13.7.5 Australia
13.7.5.1 Market Size and Forecast, By Type
13.7.5.2 Market Size and Forecast, By Product Type
13.7.5.3 Market Size and Forecast, By Test Type
13.7.5.4 Market Size and Forecast, By Application
13.7.5.5 Market Size and Forecast, By End Users
13.7.6 New Zealand
13.7.6.1 Market Size and Forecast, By Type
13.7.6.2 Market Size and Forecast, By Product Type
13.7.6.3 Market Size and Forecast, By Test Type
13.7.6.4 Market Size and Forecast, By Application
13.7.6.5 Market Size and Forecast, By End Users
13.7.7 Singapore
13.7.7.1 Market Size and Forecast, By Type
13.7.7.2 Market Size and Forecast, By Product Type
13.7.7.3 Market Size and Forecast, By Test Type
13.7.7.4 Market Size and Forecast, By Application
13.7.7.5 Market Size and Forecast, By End Users
13.7.8 Malaysia
13.7.8.1 Market Size and Forecast, By Type
13.7.8.2 Market Size and Forecast, By Product Type
13.7.8.3 Market Size and Forecast, By Test Type
13.7.8.4 Market Size and Forecast, By Application
13.7.8.5 Market Size and Forecast, By End Users
13.7.9 Rest of Asia
13.7.9.1 Market Size and Forecast, By Type
13.7.9.2 Market Size and Forecast, By Product Type
13.7.9.3 Market Size and Forecast, By Test Type
13.7.9.4 Market Size and Forecast, By Application
13.7.9.5 Market Size and Forecast, By End Users
14 Latin America Non-Invasive Cancer Diagnostics Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Non-Invasive Cancer Diagnostics Market Share Analysis, By Type
14.3 Latin America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Product Type
14.4 Latin America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Test Type
14.5 Latin America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Application
14.6 Latin America Non-Invasive Cancer Diagnostics Market Size and Forecast, By End Users
14.7 Latin America Non-Invasive Cancer Diagnostics Market Size and Forecast, By Country
14.7.1 Brazil
14.7.1.1 Market Size and Forecast, By Type
14.7.1.2 Market Size and Forecast, By Product Type
14.7.1.3 Market Size and Forecast, By Test Type
14.7.1.4 Market Size and Forecast, By Application
14.7.1.5 Market Size and Forecast, By End Users
14.7.2 Argentina
14.7.2.1 Market Size and Forecast, By Type
14.7.2.2 Market Size and Forecast, By Product Type
14.7.2.3 Market Size and Forecast, By Test Type
14.7.2.4 Market Size and Forecast, By Application
14.7.2.5 Market Size and Forecast, By End Users
14.7.3 Colombia
14.7.3.1 Market Size and Forecast, By Type
14.7.3.2 Market Size and Forecast, By Product Type
14.7.3.3 Market Size and Forecast, By Test Type
14.7.3.4 Market Size and Forecast, By Application
14.7.3.5 Market Size and Forecast, By End Users
14.7.4 Peru
14.7.4.1 Market Size and Forecast, By Type
14.7.4.2 Market Size and Forecast, By Product Type
14.7.4.3 Market Size and Forecast, By Test Type
14.7.4.4 Market Size and Forecast, By Application
14.7.4.5 Market Size and Forecast, By End Users
14.7.5 Chile
14.7.5.1 Market Size and Forecast, By Type
14.7.5.2 Market Size and Forecast, By Product Type
14.7.5.3 Market Size and Forecast, By Test Type
14.7.5.4 Market Size and Forecast, By Application
14.7.5.5 Market Size and Forecast, By End Users
14.7.6 Venezuela
14.7.6.1 Market Size and Forecast, By Type
14.7.6.2 Market Size and Forecast, By Product Type
14.7.6.3 Market Size and Forecast, By Test Type
14.7.6.4 Market Size and Forecast, By Application
14.7.6.5 Market Size and Forecast, By End Users
14.7.7 Rest of Latin America
14.7.7.1 Market Size and Forecast, By Type
14.7.7.2 Market Size and Forecast, By Product Type
14.7.7.3 Market Size and Forecast, By Test Type
14.7.7.4 Market Size and Forecast, By Application
14.7.7.5 Market Size and Forecast, By End Users
15 Middle East Non-Invasive Cancer Diagnostics Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Non-Invasive Cancer Diagnostics Market Share Analysis, By Type
15.3 Middle East Non-Invasive Cancer Diagnostics Market Size and Forecast, By Product Type
15.4 Middle East Non-Invasive Cancer Diagnostics Market Size and Forecast, By Test Type
15.5 Middle East Non-Invasive Cancer Diagnostics Market Size and Forecast, By Application
15.6 Middle East Non-Invasive Cancer Diagnostics Market Size and Forecast, By End Users
15.7 Middle East Non-Invasive Cancer Diagnostics Market Size and Forecast, By Country
15.7.1 Saudi Arabia
15.7.1.1 Market Size and Forecast, By Type
15.7.1.2 Market Size and Forecast, By Product Type
15.7.1.3 Market Size and Forecast, By Test Type
15.7.1.4 Market Size and Forecast, By Application
15.7.1.5 Market Size and Forecast, By End Users
15.7.2 UAE
15.7.2.1 Market Size and Forecast, By Type
15.7.2.2 Market Size and Forecast, By Product Type
15.7.2.3 Market Size and Forecast, By Test Type
15.7.2.4 Market Size and Forecast, By Application
15.7.2.5 Market Size and Forecast, By End Users
15.7.3 Egypt
15.7.3.1 Market Size and Forecast, By Type
15.7.3.2 Market Size and Forecast, By Product Type
15.7.3.3 Market Size and Forecast, By Test Type
15.7.3.4 Market Size and Forecast, By Application
15.7.3.5 Market Size and Forecast, By End Users
15.7.4 Kuwait
15.7.4.1 Market Size and Forecast, By Type
15.7.4.2 Market Size and Forecast, By Product Type
15.7.4.3 Market Size and Forecast, By Test Type
15.7.4.4 Market Size and Forecast, By Application
15.7.4.5 Market Size and Forecast, By End Users
15.7.5 South Africa
15.7.5.1 Market Size and Forecast, By Type
15.7.5.2 Market Size and Forecast, By Product Type
15.7.5.3 Market Size and Forecast, By Test Type
15.7.5.4 Market Size and Forecast, By Application
15.7.5.5 Market Size and Forecast, By End Users
15.7.6 Rest of Middle East & Africa
15.7.6.1 Market Size and Forecast, By Type
15.7.6.2 Market Size and Forecast, By Product Type
15.7.6.3 Market Size and Forecast, By Test Type
15.7.6.4 Market Size and Forecast, By Application
15.7.6.5 Market Size and Forecast, By End Users
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 Abbott (U.S.)
17.1.1 Overview
17.1.2 Offerings
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2 Thermo Fisher Scientific, Inc. (U.S.)
17.2.1 Overview
17.2.2 Offerings
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3 Illumina, Inc. (U.S.)
17.3.1 Overview
17.3.2 Offerings
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 QIAGEN (Germany)
17.4.1 Overview
17.4.2 Offerings
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 F. Hoffmann-La Roche Ltd (Switzerland)
17.5.1 Overview
17.5.2 Offerings
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 Agilent Technologies, Inc. (U.S.)
17.6.1 Overview
17.6.2 Offerings
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 Quest Diagnostics Incorporated. (U.S.)
17.7.1 Overview
17.7.2 Offerings
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 Merck KGaA, (Germany)
17.8.1 Overview
17.8.2 Offerings
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 Hologic, Inc. (U.S.)
17.9.1 Overview
17.9.2 Offerings
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 BD. (U.S.)
17.10.1 Overview
17.10.2 Offerings
17.10.3 Key Financials
17.10.4 Business Segment & Geographic Overview
17.10.5 Key Market Developments
17.10.6 Key Strategies
